

28 February 2011

TENDER RESULTS

The PHARMAC Board (or Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010.

As discussed in our 2010 tender consultation document, we intend to notify tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. We have, therefore, altered the layout of this notification letter.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm **11th March 2011**. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp.

2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Abacavir sulphate	Oral liq 20 mg per ml; 240 ml OP, bottle	\$100.00	\$50.00	Ziagen (GSK)	1 May 2011	1 August 2011

Chemical name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Abacavir sulphate	Tab 300 mg; 60 tablets, blister	\$458.00	\$229.00	Ziagen (GSK)	1 May 2011	1 August 2011
Amitriptyline	Tab 25 mg; 100 tablets, blister	\$3.40	\$1.85	Amitrip (Mylan)	1 April 2011	1 July 2011
Amitriptyline	Tab 50 mg; 100 tablets, blister	\$5.20	\$3.60	Amitrip (Mylan)	1 April 2011	1 July 2011
Doxazosin mesylate	Tab 2 mg; 500 tablets, bottle	\$22.85	\$8.23	Apo-Doxazosin (Apotex)	1 April 2011	1 July 2011
Doxazosin mesylate	Tab 4 mg; 500 tablets, bottle	\$30.26	\$12.40	Apo-Doxazosin (Apotex)	1 April 2011	1 July 2011
Exemestane*	Tab 25 mg; 30 tablets, blister	\$26.55 (\$175.00)	\$22.57	Aromasin (Pfizer)	1 April 2011	1 July 2011
Isosorbide mononitrate	Tab long-acting 40 mg; 30 tablets, blister	\$14.84	\$7.50	Corangin (Novartis)	1 April 2011	1 July 2011
Isosorbide mononitrate	Tab 20 mg; 100 tablets, blister	\$18.00	\$17.10	Ismo 20 (Riemser)	1 April 2011	1 July 2011
Metoclopramide hydrochloride	Tab 10 mg; 100 tablets, bottle	\$5.15	\$3.95	Metamide (Mylan)	1 April 2011	1 July 2011
Norfloxacin	Tab 400 mg; 100 tablets, bottle	\$22.50	\$15.45	Arrow-Norfloxacin (Arrow)	1 April 2011	1 July 2011

* The current Special Authority for Alternate Subsidy applying to exemestane tab 25 mg in Section B of the Pharmaceutical Schedule will be removed from 1 April 2011

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Ipratropium bromide	Aqueous nasal spray, 0.03%; 15 ml bottle, 1 bottle	\$12.66 (per 30 ml)	\$4.03	Univent (Rex Medical)	1 April 2011	1 June 2011	1 September 2011	Apo-Ipravent (Apotex)
Tamoxifen citrate	Tab 20 mg; 100 tablets, blister	\$11.10	\$8.75	Genox (Mylan)	1 April 2011	1 June 2011	1 September 2011	Tamoxifen Sandoz (Sandoz)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Pack price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Abacavir sulphate	Oral liq 20 mg per ml; 240 ml, bottle	\$50.00	Ziagen (GSK)	1%	1 May 2011	1 July 2011
Abacavir sulphate	Tab 300 mg; 60 tablets, blister	\$229.00	Ziagen (GSK)	1%	1 May 2011	1 July 2011
Isosorbide mononitrate	Tab long-acting 40 mg; 30 tablets, blister	\$7.50	Corangin (Novartis)	1%	1 April 2011	1 June 2011

4. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Amitriptyline	Tab 25 mg; 100 tablets, blister	\$3.40	\$1.85	Amitrip (Mylan)	1%	1 April 2011	1 June 2011

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Amitriptyline	Tab 50 mg; 100 tablets, blister	\$5.20	\$3.60	Amitrip (Mylan)	1%	1 April 2011	1 June 2011
Doxazosin mesylate	Tab 2 mg; 500 tablets, bottle	\$22.85	\$8.23	Apo-Doxazosin (Apotex)	1%	1 April 2011	1 June 2011
Doxazosin mesylate	Tab 4 mg 500 tablets, bottle	\$30.26	\$12.40	Apo-Doxazosin (Apotex)	1%	1 April 2011	1 June 2011
Exemestane	Tab 25 mg; 30 tablets, blister	\$175.00	\$22.57	Aromasin (Pfizer)	1%	1 April 2011	1 June 2011
Isosorbide mononitrate	Tab 20 mg; 100 tablets, blister	\$18.00	\$17.10	Ismo 20 (Riemser)	1%	1 April 2011	1 June 2011
Metoclopramide hydrochloride	Tab 10 mg; 100 tablets, bottle	\$5.15	\$3.95	Metamide (Mylan)	1%	1 April 2011	1 June 2011
Norfloxacin	Tab 400 mg; 100 tablets, bottle	\$22.50	\$15.45	Arrow-Norfloxacin (Arrow)	1%	1 April 2011	1 June 2011

5. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Tamoxifen citrate	Tab 20 mg; 100 tablets, blister	\$11.10	\$8.75	Genox (Mylan)	1%	1 April 2011	1 June 2011	Tamoxifen Sandoz (Sandoz)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2010/11 Invitation to Tender, dated 2 November 2010:

Chemical Name	Line Item
Benzbromarone	Tab 25 mg
Benzbromarone	Tab 50 mg
Benzbromarone	Tab 100 mg
Midazolam	Tab 7.5 mg

For products included in the 2008/09 Invitation to Tender, 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.